Related Experiment Videos
Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned
1Department of Anesthesiology and Intensive Care Medicine, University Hospital, Jena, Germany. Konrad.Reinhart@med.uni-jena.de
Objective:
Tumor necrosis factor (TNF) is an important mediator involved in the pathogenesis of sepsis. We review clinical studies investigating the efficacy of anti-TNF therapy in decreasing mortality rates in septic patients.
Data Sources:
We conducted a computerized bibliographic search of randomized, clinical, multicenter trials studying the effects of anti-TNF therapy in the treatment of sepsis. We included all primary studies, reviewed all published meta-analyses, and contacted primary investigators of multicenter trials where necessary.
Data Synthesis:
Almost all randomized studies targeting TNF during sepsis show a small, albeit nonsignificant, benefit in decreasing mortality. Strategies using monoclonal antibodies are more effective than are strategies using TNF receptor proteins. Analysis of randomized multicenter trials shows a small but significant benefit with anti-TNF therapeutic strategies. Furthermore, a recent study in 2634 septic patients using a murine anti-TNF antibody shows a 3.6% significant benefit in reducing mortality.
Conclusions:
Anti-TNF strategies are only partially effective in patients with sepsis. Although individual studies show small, nonsignificant benefits, analysis of all trial data as well as data from a recent trial in a large population of septic patients show that anti-TNF strategies may confer a small survival benefit. Better characterization of patients and a more multimodal approach by concomitantly targeting other mediators involved in sepsis may be helpful in enlarging the clinical benefit of anti-TNF therapy.
Insights
Anti-tumor necrosis factor (TNF) therapies offer a small survival benefit for sepsis patients, particularly monoclonal antibodies. Further research into patient selection and combination therapies is recommended for improved outcomes.
Area of Science:
- Immunology
- Critical Care Medicine
- Pharmacology
Background:
- Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection.
- Tumor necrosis factor (TNF) plays a critical role in the inflammatory cascade during sepsis pathogenesis.
- Targeting TNF has been explored as a therapeutic strategy to mitigate sepsis-induced mortality.
Purpose of the Study:
- To review clinical studies on the efficacy of anti-TNF therapy in reducing mortality rates in patients with sepsis.
- To evaluate the effectiveness of different anti-TNF therapeutic approaches.
Main Methods:
- Comprehensive computerized bibliographic search of randomized, multicenter clinical trials.
- Inclusion of all primary studies and published meta-analyses.
- Contacting investigators for additional data where necessary.
Main Results:
- Most randomized studies show a small, non-significant mortality benefit with anti-TNF therapy.
- Monoclonal antibody strategies demonstrate greater efficacy compared to TNF receptor proteins.
- Analysis of multicenter trials and a large recent study indicate a small but significant survival benefit.
Conclusions:
- Anti-TNF therapies provide partial efficacy in sepsis management.
- While individual studies show limited benefits, aggregated data suggest a modest survival advantage.
- Future strategies should focus on patient stratification and combination therapies targeting multiple inflammatory mediators.